Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Saved in:
| Title: | Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial. |
|---|---|
| Authors: | Shimura M; Tokyo Medical University Hachioji Medical Center, 1163, Tatemachi, Hachioji-shi, Tokyo, 193-0998, Japan. masahiko@v101.vaio.ne.jp., Kitano S; Tokyo Women's Medical University Hospital, Tokyo, Japan., Ogata N; Nara Medical University Hospital, Nara, Japan., Mitamura Y; Tokushima University Graduate School, Tokushima, Japan., Oh H; Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan., Ochi H; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Ohsawa S; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Hirakata A; Kyorin University School of Medicine, Tokyo, Japan. |
| Corporate Authors: | YOSEMITE and RHINE Investigators |
| Source: | Japanese journal of ophthalmology [Jpn J Ophthalmol] 2023 May; Vol. 67 (3), pp. 264-279. Date of Electronic Publication: 2023 Mar 10. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Springer Tokyo Country of Publication: Japan NLM ID: 0044652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1613-2246 (Electronic) Linking ISSN: 00215155 NLM ISO Abbreviation: Jpn J Ophthalmol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
